TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT06419374: A Phase 3 Study to Evaluate the Efficacy and Safety of Pegozafermin in Subjects With Compensated Cirrhosis Due to Metabolic Dysfunction-Associated Steatohepatitis (MASH) (ENLIGHTEN-Cirrhosis)

Sponsor: Hoffmann-La Roche · Phase: PHASE3 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 1800 pts

Competing Trials Overlap

11 Active Trials

Excess Burn Exposure

$11,455,992

Rescue Site Savings

+$7,543,040

Unlock Full NCT06419374 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06419374 Rescue Dossier →